Updated: May 1, 2006
Children in the United States can receive up to 20 vaccinations to protect against 11 diseases in their first 2 years of life. With the current immunization schedule it is possible that a child could receive as many as 5 separate injections during a single office visit.1
For that reason—and because more vaccines against fatal diseases are being developed—manufacturers have been developing combination vaccines. With the use of combination vaccines the number of injections can be reduced without reducing the number of diseases against which a child is protected. Also, this might be a good way for the vaccine manufacturers to market their vaccines.
A combination vaccine is a vaccine that consists of 2 or more separate immunogens (elements that produce an immune response from the body) physically combined into a single product.2
Combination vaccines aim to prevent multiple diseases or 1 disease caused by different types of the same organism.3
An example of a combination vaccine is the measles-mumps-rubella (MMR) vaccine. Other combination vaccines include:
In addition to reducing the number of injections—and therefore the amount of pain the children experience—the use of combination vaccines might:
However, there are some challenges that researchers, manufacturers, regulatory agencies, policy makers and providers face regarding combination vaccines.
The first challenge is how to test the vaccine for effectiveness. When there is no licensed vaccine, researchers conduct an efficacy trial where vaccine is given to one group of persons—experimental group—and a placebo (for example, water with salt) to another group—control group. If fewer people in the experimental group end up acquiring the disease than in the control group, the vaccine proves to be effective.
However, in the case of combination vaccines, it would be unethical to deny existing vaccines (for example, the single licensed components in the vaccine being tested) to the control group. So researchers compare immune responses and adverse reactions of the separate components of the vaccine to those for the candidate combination vaccine.
Manufacturers sometimes find that the elements that they want to combine in a vaccine might not be compatible or stable. In other words, when 2 or more antigens are combined, they may not work as well as they do individually.
Consequently, the US Food and Drug Administration, requires that “a biological product may combine two or more safe and effective components…when combining of the active ingredients does not decrease the purity, potency, safety, or effectiveness of any of the individual active components.”2 Thus the evaluation of the safety and efficacy of combined vaccines is a complex process.3
Different manufacturers may apply for licensure for combination vaccines that contain different vaccine components—and the components from different manufacturers may differ. Therefore, health care providers must consider how best to use the competing vaccine products.
Each manufacturer develops and produces vaccines by its own methods. In addition, the various manufacturers may make different combinations of vaccines. Because vaccines from different manufacturers are often not tested for their interchangeability, vaccine policy makers must make recommendations about how best to utilize the various combination vaccines.4
For example, the CDC guidance on the use of combination vaccines is as follows: “A combination vaccine may be used when one or more components are indicated, none of the other components are contraindicated, and if the combination vaccine is approved by FDA or recommended by a national advisory group (such as ACIP) for that dose in the schedule, unless this would lead to a needed vaccine dose being withheld.”5
Although the development, evaluation, and use of combination vaccines is complex, these types of vaccines should simplify the immunization schedule and reduce the number of injections that children receive.